Cigna Investments Inc. New boosted its position in shares of Eli Lilly And Co (NYSE:LLY) by 5.0% during the first quarter, Holdings Channel.com reports. The fund owned 31,465 shares of the company’s stock after acquiring an additional 1,491 shares during the quarter. Cigna Investments Inc. New’s holdings in Eli Lilly And Co were worth $4,365,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in LLY. Global Retirement Partners LLC raised its stake in Eli Lilly And Co by 2.3% during the 4th quarter. Global Retirement Partners LLC now owns 8,259 shares of the company’s stock worth $1,085,000 after acquiring an additional 189 shares during the period. J.W. Cole Advisors Inc. bought a new stake in Eli Lilly And Co during the 4th quarter worth approximately $411,000. Nwam LLC raised its stake in Eli Lilly And Co by 8.4% during the 4th quarter. Nwam LLC now owns 3,665 shares of the company’s stock worth $482,000 after acquiring an additional 284 shares during the period. Telos Capital Management Inc. grew its holdings in Eli Lilly And Co by 8.2% during the 4th quarter. Telos Capital Management Inc. now owns 3,314 shares of the company’s stock valued at $436,000 after buying an additional 250 shares in the last quarter. Finally, Chicago Partners Investment Group LLC grew its holdings in Eli Lilly And Co by 9.4% during the 4th quarter. Chicago Partners Investment Group LLC now owns 3,327 shares of the company’s stock valued at $471,000 after buying an additional 287 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.
In related news, SVP Aarti S. Shah sold 2,000 shares of the firm’s stock in a transaction on Tuesday, April 14th. The stock was sold at an average price of $150.00, for a total value of $300,000.00. Following the completion of the sale, the senior vice president now directly owns 19,087 shares in the company, valued at $2,863,050. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Lilly Endowment Inc sold 12,663 shares of the firm’s stock in a transaction on Monday, April 27th. The stock was sold at an average price of $163.60, for a total value of $2,071,666.80. Following the completion of the sale, the insider now owns 112,197,641 shares of the company’s stock, valued at $18,355,534,067.60. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 906,320 shares of company stock valued at $132,984,238. 0.09% of the stock is owned by corporate insiders.
A number of equities research analysts have issued reports on LLY shares. Zacks Investment Research cut their price objective on shares of Eli Lilly And Co to $156.00 in a report on Wednesday, April 29th. Barclays started coverage on shares of Eli Lilly And Co in a report on Thursday, February 27th. They set an “overweight” rating for the company. Morgan Stanley lowered shares of Eli Lilly And Co from an “overweight” rating to an “equal weight” rating in a report on Sunday, April 19th. UBS Group lowered shares of Eli Lilly And Co from a “buy” rating to a “neutral” rating and increased their price objective for the company from $157.00 to $158.00 in a report on Monday, April 20th. Finally, Cantor Fitzgerald increased their price objective on shares of Eli Lilly And Co from $156.00 to $185.00 and gave the company an “overweight” rating in a report on Friday, April 24th. Four research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $158.64.
Shares of LLY stock traded down $1.12 on Friday, reaching $151.16. The company’s stock had a trading volume of 2,322,495 shares, compared to its average volume of 2,875,585. The stock’s fifty day simple moving average is $152.85 and its 200-day simple moving average is $136.00. Eli Lilly And Co has a 1 year low of $101.36 and a 1 year high of $164.90. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 4.37. The company has a market capitalization of $145.65 billion, a price-to-earnings ratio of 24.99, a price-to-earnings-growth ratio of 1.82 and a beta of 0.25.
Eli Lilly And Co (NYSE:LLY) last issued its quarterly earnings results on Thursday, April 23rd. The company reported $1.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.48 by $0.27. The company had revenue of $5.86 billion during the quarter, compared to the consensus estimate of $5.48 billion. Eli Lilly And Co had a return on equity of 194.18% and a net margin of 23.97%. Eli Lilly And Co’s revenue was up 15.1% on a year-over-year basis. During the same period last year, the company earned $1.33 earnings per share. Equities research analysts forecast that Eli Lilly And Co will post 6.81 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be given a $0.74 dividend. The ex-dividend date is Thursday, May 14th. This represents a $2.96 dividend on an annualized basis and a yield of 1.96%. Eli Lilly And Co’s dividend payout ratio is presently 49.01%.
Eli Lilly And Co Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Featured Story: Price-Sales Ratio
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.